CIK 1813845
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 100.00% | 6 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | ACTU | ACTUATE THERAPEUTICS, INC. | Health Care | 52.09% |
| 2 | IRD | Opus Genetics, Inc. | Health Care | 31.70% |
| 3 | CGTX | COGNITION THERAPEUTICS INC | Health Care | 8.63% |
| 4 | RNTX | Rein Therapeutics, Inc. | Health Care | 4.87% |
| 5 | LTRN | Lantern Pharma Inc. | Health Care | 2.24% |
| 6 | INAB | IN8BIO, INC. | Health Care | 0.47% |
6/6 names classified · sector 100.0% of weight · industry 100.0% · mkt cap 100.0%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 100.0% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/6 names) · unclassified 100.0%: ACTU, IRD, CGTX, RNTX, LTRN, INAB. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | ACTUACTUATE THERAPEUTICS INC | 10,049,996 | $28M | 52.1% | HOLD |
| 2 | IRDOPUS GENETICS INC | 3,683,429 | $17M | 31.7% | HOLD |
| 3 | CGTXCOGNITION THERAPEUTICS INC | 6,000,000 | $5M | 8.6% | HOLD |
| 4 | RNTXREIN THERAPEUTICS INC | 1,982,375 | $3M | 4.9% | ADD 17% |
| 5 | LTRNLANTERN PHARMA INC | 864,435 | $1M | 2.2% | TRIM −14% |
| 6 | INABIN8BIO INC | 167,805 | $248,351 | 0.5% | TRIM −34% |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| ACTUACTUATE THERAPEUTICS INC | 9.9M | 9.9M | 10.0M | 10.0M | 10.0M | 10.0M | $28M |
| IRDOPUS GENETICS INC | 995K | 995K | 3.7M | 3.7M | 3.7M | 3.7M | $17M |
| CGTXCOGNITION THERAPEUTICS INC | 6.0M | 6.0M | 6.0M | 6.0M | 6.0M | 6.0M | $5M |
| RNTXREIN THERAPEUTICS INC | 1.7M | 1.7M | 1.7M | 1.7M | 1.7M | 2.0M | $3M |
| LTRNLANTERN PHARMA INC | 1.2M | 1.2M | 1.1M | 1.0M | 1.0M | 864K | $1M |
| INABIN8BIO INC | — | — | — | — | 253K | 168K | $248,351 |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
